Itraconazole and Clarithromycin as Ketoconazole Alternatives for Clinical CYP3A Inhibition Studies
- 1 May 2014
- journal article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 95 (5), 473-476
- https://doi.org/10.1038/clpt.2014.41
Abstract
High-dose ketoconazole (400 mg q.d. for ≥5 days) has been the gold-standard strong cytochrome P450 3A (CYP3A) inhibitor in drug development drug-drug interaction (DDI) studies. In 2013, the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) advised against using this ketoconazole regimen following review of clinical safety reports. We systematically evaluated 19 strong CYP3A inhibitors from regulatory guidances and a literature database to identify itraconazole (200 mg b.i.d. on day 1, q.d. on days 2-6) and clarithromycin (500 mg b.i.d. for 7 days) as acceptable ketoconazole alternatives.This publication has 5 references indexed in Scilit:
- Optimization of Drug-Drug Interaction Study Design: Comparison of Minimal Physiologically Based Pharmacokinetic Models on Prediction of CYP3A Inhibition by KetoconazoleDrug Metabolism and Disposition, 2013
- Physiologically Based Pharmacokinetic Modeling of Intestinal First-Pass Metabolism of CYP3A Substrates with High Intestinal ExtractionDrug Metabolism and Disposition, 2011
- Accurate Prediction of Dose-Dependent CYP3A4 Inhibition by Itraconazole and Its Metabolites From In Vitro Inhibition DataClinical Pharmacology & Therapeutics, 2010
- Physiologically Based Pharmacokinetic Model of Mechanism-Based Inhibition of CYP3A by ClarithromycinDrug Metabolism and Disposition, 2009
- Contribution of Itraconazole Metabolites to Inhibition of CYP3A4 In VivoClinical Pharmacology & Therapeutics, 2007